UroGen Pharma to Host UGN-102 Virtual Event on June 13, 2024

UroGen Pharma, a biotechnology firm listed on Nasdaq under the ticker URGN, is set to host a virtual data event for its Phase 3 ENVISION trial on June 13, 2024, at 11:00 a.m. Eastern Time. The event will spotlight UGN-102 (mitomycin) for intravesical solution aimed at individuals with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

The ENVISION event will reveal 12-month durability of response data, focusing on patients who achieved a complete response three months post the six-week UGN-102 treatment regimen. Key Opinion Leaders will contribute to a panel discussion on the treatment strategies for LG-IR-NMIBC during the event.

Participants can register for the webinar via the Events & Presentations section of UroGen's Investor Relations website. A replay will be available on the same site after the live broadcast.

About UGN-102

UGN-102 is an experimental mitomycin formulation designed for intravesical use to treat LG-IR-NMIBC. This drug leverages UroGen’s proprietary RTGel® technology, creating a hydrogel-based sustained-release formulation aimed at prolonging the bladder tissue’s exposure to mitomycin. This approach allows for tumor treatment without surgical intervention. Administered through a standard urinary catheter in an outpatient setting, UGN-102 may become the first non-surgical primary treatment option for LG-IR-NMIBC, a cancer type known for its high recurrence and multiple surgeries.

About UroGen Pharma Ltd.

UroGen Pharma Ltd. focuses on developing and commercializing groundbreaking treatments for urothelial and specialty cancers, driven by the belief that patients deserve superior options. The company has created the RTGel® reverse-thermal hydrogel platform, which potentially enhances the therapeutic profiles of existing drugs. This technology aims to increase the duration of urinary tract tissue exposure to medications, potentially making local therapy more effective.

UroGen's product lineup includes JELMYTO® (mitomycin) for pyelocalyceal solution and the investigational UGN-102 (mitomycin) for intravesical solution for LG-IR-NMIBC patients. Both treatments are designed to eliminate tumors non-surgically. Headquartered in Princeton, NJ, UroGen also operates in Israel.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!